Brief Summary
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advancedat a late stage, far along breast cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs, and patients with metastatic high-grade serious ovarian cancer.
Intervention / Treatment
- Drug: AZD8421
- Drug: Camizestrant
- Drug: Ribociclib
- Drug: Palbociclib
- Drug: Abemaciclib
Inclusion Criteria:
- Female participants only, aged 18 or above
- Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical study is the best option for their next treatment based on response to and/or tolerability of prior therapy.
- Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP.
- ECOG/WHO performance status 0 to 1, and a minimum life expectancy of 12 weeks.
- At least one lesion that is measurable and/or non-measurable, as per RECIST v1.1 and that can be accurately assessed at baseline and is suitable for repeated assessment.